Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + TKIs for TFR in CP-CML
NCT03610971Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in chronic myeloid leukemia (CML), sponsored by Moffitt Cancer Center. Started Nov 2019; status: active, not recruiting.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03610971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610971.